Webinar: Elevating Customer Experience Through Quality
Discover your potential savings with our ROI Calculator
Self-guided Product Tours
Product Demo Videos
Pricing
Recent Analyst Insights
Featured Analyst Insights
2026 Gartner® Magic Quadrant™ for Quality Management System Software
Recent Blogs
Recent Infographics
Recent Case Studies
Featured Case Study
ComplianceQuest Medical Devices QMS Success Stories eBook
Recent Checklists
Featured Checklist
Complaint Handling Process for MedTech and Life Science Companies
Course Offerings
Recent CQ Guides
Datasheets
Brochures
Demo Center
Videos
Podcasts
Recent Webinars
Webinar
Unlocking the Value of Complaints
Recent Whitepapers
Whitepaper
Why You Need to Digitally Transform Your QMS
Compliance
Toolkits
Infographic
Safety Technology Trends to Watch in 2023 (Infographic)
Recent Toolkits
Events and Webinars
Events
Upcoming Webinars
Featured Event
PDA/FDA Joint Regulatory Conference 2026
14 Sep, 2026
Washington, DC
About
About ComplianceQuest
ComplianceQuest is the #1 AI-powered Quality, Risk, and Compliance (QRC) platform that connects Product, Quality, Manufacturing, People, Suppliers and Customers in a single system.
Built on Salesforce, the platform delivers end-to-end visibility, AI-driven intelligence, and enterprise-scale execution, enabling organizations to manage risk, ensure regulatory compliance, and turn quality into a driver of growth.
Meet the Leadership Team
Careers
Where Your Career Takes Flight: Join our dynamic team and be part of an innovative, collaborative and rewarding workplace culture.
Corporate Citizenship
Impact Through Action: How the ComplianceQuest team supports social causes and community engagement
Customers & Testimonials
Newsroom
The Pulse of ComplianceQuest: Our newsroom shares stories of innovation, progress, and change
Partners
Stronger Together: How our partnerships drive success and innovation
Upcoming Events
One AI-powered, Salesforce-native platform unifying Quality Management, EHS, Supplier Quality, and GxP Compliance for pharmaceutical manufacturers — across drug manufacturing, API, biologics, generics, OTC, CMO, and clinical operations.
The FDA issued over 190 warning letters to drug and biologics manufacturers in FY2024 alone — 113 of which were inspection-based. The root cause in most cases is not a lack of knowledge about the regulations. It is disconnected, reactive quality systems that make compliance invisible until an inspector or a patient event forces it into view.
Pharmaceutical manufacturers at the enterprise level operate under some of the most exacting quality obligations in any regulated industry. Every batch, every deviation, every supplier material, every SOP change, and every validation activity must be documented, traceable, and defensible — simultaneously across 21 CFR, EU GMP, ICH guidelines, and global health authority requirements.
ComplianceQuest is built for exactly this environment — a GxP-by-design, AI-powered platform that unifies your entire quality, safety, and supplier management operation in one validated cloud system.
All modules share one data model, one audit trail, and one CQ.AI™ intelligence layer — with GxP controls by design, not by workaround.
ComplianceQuest is built GxP-compliant from the ground up. Every record carries time-stamped, non-repudiable electronic signatures. Every workflow generates a complete, immutable audit trail. Every configuration is managed through a validated change control process. IQ/OQ/PQ validation documentation packages are included — so your computer system validation programme is not starting from zero. This is what 21 CFR Part 11 and EU GMP Annex 11 compliance-by-design means in practice.
A complete, GxP-validated eQMS aligned with 21 CFR Parts 210/211, EU GMP, and ICH Q10. Closed-loop workflows connect deviations, OOS results, CAPA, change control, and training in one validated system — with CQ.AI™ intelligence detecting patterns across the full quality event landscape.
GMP-controlled SOP lifecycle management with 21 CFR Part 11 e-signatures, automated approval routing, controlled distribution, and periodic review scheduling — with complete revision history and linkage to training records ensuring every employee is qualified to the current document version.
Structured pharmaceutical deviation classification (planned/unplanned), investigation workflows, root cause analysis, impact assessment, regulatory reporting triggers, and CAPA initiation — with CQ.AI™ cross-referencing historical deviations to accelerate root cause identification and prevent recurring events.
FDA-guidance-aligned Out-of-Specification (OOS) and Out-of-Trend (OOT) investigation workflows — covering Phase I lab investigation, Phase II full investigation, and regulatory reporting. Connected to batch record management and stability monitoring for complete analytical data traceability.
Structured pharmaceutical CAPA with risk-based prioritisation, root cause analysis (5-Why, Fishbone, Fault Tree), corrective and preventive action plans, implementation tracking, and mandatory effectiveness checks — preventing the repeat observations that fuel FDA warning letters.
Risk-based pharmaceutical change control — categorising changes (minor, major, critical), routing for cross-functional review, triggering regulatory impact assessments, linking to validation and stability requirements, and managing regulatory filing obligations across all global markets where the product is registered.
Internal GMP audit, supplier audit, and pre-inspection preparation management — with digital evidence packages, observation response workflows, and FDA 483 and EMA deficiency response tracking. CQ.AI™ pre-inspection gap analysis identifies potential findings before the inspector arrives.
GMP-compliant complaint intake, investigation, and regulatory reporting — with automatic MDR and pharmacovigilance reporting triggers, complaint trend analytics, and linkage to batch genealogy records for rapid traceability when complaint investigations identify potential product quality issues.
Role-based GMP training assignment with automatic triggers on SOP revisions, CAPA actions, and regulatory changes. Electronic training acknowledgment, qualification records, and real-time completion dashboards — ensuring inspectors can demonstrate a fully qualified workforce for every GMP activity.
Unified EHS management for pharmaceutical manufacturing environments — ISO 45001 occupational safety, chemical and hazardous substance management (COSHH, OSHA HazCom), environmental monitoring and ISO 14001 compliance, and potent compound handling safety — all integrated with the QMS for a true closed-loop QHSE system.
Occupational exposure limit (OEL) and occupational exposure band (OEB) management for potent APIs and cytotoxic compounds — including containment strategy documentation, engineering controls qualification, personal protective equipment (PPE) requirements, and biological monitoring programme management.
SDS library management, chemical inventory tracking, COSHH and OSHA HazCom compliance, and waste management documentation — with automatic alerts when new chemicals are introduced that require HBEL-based cleaning limit calculations or containment strategy updates.
Real-time incident and near-miss reporting with root cause analysis, regulatory notification triggers (OSHA 300 reporting), and automatic CAPA initiation — connected to the quality CAPA system so a safety incident impacting product quality is investigated and resolved in one unified workflow.
ISO 14001-aligned environmental management — aspect identification, legal register management, pharmaceutical emissions and effluent tracking, waste disposal documentation, and environmental permit management for pharmaceutical manufacturing sites with complex environmental obligations.
Scheduled and unscheduled safety inspections with digital checklists, automatic corrective action initiation, and permit-to-work management for pharmaceutical facility maintenance and engineering work — ensuring safety controls are verified before contractors and maintenance personnel access GMP areas.
GMP-compliant supplier quality management for pharmaceutical raw material, API, excipient, and packaging material suppliers — with supplier qualification workflows, GMP audit management, supplier corrective action requests (SCARs), and real-time supplier performance dashboards. PartnerQuest connects supplier quality directly into batch release decision-making.
GMP supplier onboarding — regulatory status verification, GMP certificate validation, supplier questionnaires, qualification audits, and approved vendor list (AVL) maintenance. Automatic re-qualification triggers when GMP certificates expire, audit intervals are breached, or supplier quality events reach threshold levels.
On-site and remote GMP supplier audit workflows with digital evidence capture, GMP observation classification, regulatory deficiency response tracking, and automatic CAPA initiation. Supplier audit history linked to AVL status and batch release decisions for risk-based supplier oversight.
ICH Q7 and 21 CFR Part 211-aligned raw material and API qualification workflows — identity testing, certificate of analysis review, specification comparison, and approved supplier material release — with batch-to-supplier traceability supporting product recall readiness and regulatory inquiry response.
Issue, track, and close supplier corrective action requests with structured root cause analysis, corrective action plans, and effectiveness verification — with automatic escalation when suppliers miss response deadlines and automatic AVL status review when SCAR severity warrants re-qualification.
Real-time supplier scorecards tracking quality event frequency, delivery performance, SCAR response time, and GMP certification status — with CQ.AI™ predictive risk scoring identifying at-risk suppliers before material quality issues reach your production batches.
ComplianceQuest is GxP-validated by design — and accelerates the validation of CQ itself through included IQ/OQ/PQ documentation packages, test scripts, and validation protocols. GAMP 5 risk-based validation approach with category-based testing scope, supplier audit documentation, and ongoing compliance maintenance through the Salesforce-managed infrastructure.
Validation Master Plan (VMP) document management with scope definition, validation policy, facility and equipment validation status tracking, and revalidation trigger management — providing a single, authoritative validation compliance overview for health authority inspection.
IQ, OQ, and PQ protocol management for pharmaceutical manufacturing equipment, utilities, and facilities — with qualification documentation, re-qualification scheduling, and change-triggered revalidation workflows. Equipment qualification records linked to cleaning validation and process validation for complete equipment-product traceability.
ICH Q10 and FDA process validation guidance-aligned CPV programme management — with statistical trend analysis of critical quality attributes and critical process parameters, specification limit trending, and automatic investigation triggers when process performance indices trend toward unacceptable levels.
Cleaning validation lifecycle management — method development, HBEL/PDE-based limit calculations, validation protocol management, analytical results capture, and revalidation triggers for product introductions, formulation changes, or equipment modifications affecting worst-case product selection.
GMP instrument calibration management — calibration schedules, certificate tracking, out-of-tolerance investigation workflows, and impact assessment on batches manufactured since last calibration. Calibration records linked to batch release decisions for complete instrument-to-product traceability.
Trained on millions of quality records from regulated pharmaceutical environments, CQ.AI™ delivers predictive deviation analytics, automatic OOS pattern detection, CAPA effectiveness prediction, and inspection readiness gap analysis — purpose-built for pharma quality, not a generic AI model with a compliance label.
CQ.AI™ analyses deviation patterns across batches, equipment, operators, and raw material lots — identifying recurring root causes before another investigation is opened, predicting which processes are most likely to generate deviations in the next production cycle, and enabling proactive corrective action before regulatory impact occurs.
CQ.AI™ monitors audit trail data for anomalies — unusual access patterns, potential data back-entry, record deletions, and system time discrepancies — alerting quality leadership to potential data integrity risks before they become FDA 483 observations or warning letter citations.
Pre-inspection AI-powered gap analysis — CQ.AI™ reviews your quality system records against common FDA 483 and EMA deficiency patterns, identifies potential inspector findings, and generates a prioritised remediation checklist so your team addresses gaps before the inspection, not after.
CQ.AI™ reads, summarises, and cross-references SOPs, deviation reports, CAPA records, and validation documents — reducing the manual review burden during audits, annual product reviews, and regulatory queries. Identify gaps, inconsistencies, and outdated references across your document library automatically.
CQ.AI™ automates Annual Product Review (APR) and Product Quality Review (PQR) data aggregation — compiling batch analysis results, deviation summaries, CAPA status, stability data, and complaint trends across the review period into a structured PQR report aligned with ICH Q10 and EU GMP Chapter 1 requirements.
From finished dose drug manufacturing to API synthesis, biologics, sterile manufacturing, and CMO operations — ComplianceQuest delivers sector-specific workflows and regulatory coverage without requiring separate platform instances.
Complete GMP quality management for solid dose, liquid, semi-solid, and inhalation drug product manufacturing — with 21 CFR Part 211-aligned workflows for batch record review, deviation management, OOS investigation, CAPA, and change control. CQ.AI™ predictive deviation analytics flag emerging process issues before they trigger formal investigations.
GMP-compliant electronic batch record workflows with 21 CFR Part 11 e-signatures, time-stamped audit trails, and automatic batch disposition triggers — connecting production, QC, and QA in a single, review-ready batch record that eliminates paper-based record gaps.
Structured pharmaceutical deviation management and out-of-specification (OOS) investigation workflows — with root cause analysis templates, assignable investigation phases, regulatory notification triggers, and automatic CAPA initiation. CQ.AI™ cross-references historical deviations to surface pattern-based root causes faster.
GMP-controlled SOP lifecycle management — creation, review, approval, versioning, controlled distribution, and periodic review — with automatic training triggers when SOPs are revised and complete electronic audit trails meeting 21 CFR Part 11 and EU Annex 11 requirements.
Risk-based change control workflows covering formulation changes, process changes, equipment changes, supplier changes, and site transfers — with ICH Q12-aligned lifecycle management, regulatory impact assessment, and validation planning linked to each approved change.
Role-based GMP training assignment automatically triggered by SOP revisions and change events. Electronic training acknowledgment, competency assessment, and real-time training completion dashboards — ensuring every operator and QA professional is current before accessing GMP production areas.
ICH Q7-aligned quality management for API synthesis and manufacturing — covering process validation, impurity control, starting material qualification, in-process controls, OOS investigation, and batch certification. Full traceability from raw material receipt through API batch release, supporting FDA, EU, and global health authority inspection readiness.
Incoming material qualification, vendor approval, identity testing, and GMP-compliant raw material release workflows — with supplier-to-batch traceability, quarantine management, and automatic CAPA initiation when incoming material fails specification.
ICH Q8 and Q11-aligned process validation management — covering process characterisation, design space definition, process validation protocols, and continued process verification (CPV). Technology transfer workflows with structured knowledge transfer documentation and validation equivalence assessments.
ICH Q3A/Q3B-aligned impurity specification management with stability data linkage, regulatory specification approval tracking, and automatic out-of-specification investigation triggers when analytical results exceed impurity thresholds.
GMP audit management and qualification for API starting material and intermediate suppliers — with ICH Q7-aligned supplier qualification documentation, GMP certificate tracking, audit scheduling, and corrective action management for supplier GMP deficiencies.
Site Master File (SMF) document management with version control, global regulatory submission readiness, and linkage to the quality system records that regulators reference during pre-approval inspections and surveillance audits.
GMP quality management for biologics manufacturing — covering cell culture, fermentation, purification, fill-finish, and biological product testing. FDA 21 CFR Part 600-series and EudraLex Vol. 4 Annex 2 (biological medicinal products) workflows, with batch genealogy traceability from master cell bank through final product lot release.
Quality management for advanced therapy medicinal products (ATMPs) — including autologous and allogeneic cell therapies, gene therapies, and tissue-engineered products. EU ATMP Regulation (1394/2007) and FDA CGTP (21 CFR Part 1271) workflow support with chain-of-identity and chain-of-custody traceability.
WHO GMP and 21 CFR Part 620-aligned quality management for vaccine manufacturing — covering antigen production, formulation, fill-finish, potency testing, and global lot release requirements. Stability management and post-approval commitment tracking for vaccine lifecycle management.
Quality management for biosimilar development and regulatory pathway support — with ICH Q5A/Q5B/Q5C-aligned analytical comparability study management, attribute tracking for demonstrating biosimilarity, and regulatory submission documentation linked to quality system records.
Bioprocess validation management covering upstream and downstream process validation, resin lifecycle management, virus validation, filter integrity testing, and continued process verification (CPV) — with statistical trend analysis and automatic alert triggering when CPV data indicates process drift.
Temperature-sensitive product cold chain quality management — environmental monitoring data integration, cold chain deviation management, and temperature excursion investigation workflows aligned with GMP requirements for biological products requiring controlled storage and distribution conditions.
ANDA-cycle quality management for generic drug manufacturers — covering post-approval changes (CBE-30, PAS), GDUFA II commitments, bioequivalence study management, and continuous process verification. CQ supports the compressed quality timelines that generic manufacturers need to maintain competitive time-to-market without sacrificing GMP compliance.
ICH Q12-aligned post-approval change management plan (PACMP) workflows — categorising changes by regulatory reporting category (annual report, CBE-30, prior approval supplement), managing regulatory submission documentation, and tracking health authority responses across all markets.
ICH Q1A/Q1B-aligned stability study management — protocol creation, sample pull scheduling, results capture, trending, and out-of-trend investigation. Automatic alerts when stability data trends toward specification limits, with CAPA initiation and regulatory notification workflows for shelf-life impacting findings.
Pre-inspection audit readiness management for GDUFA-funded FDA inspections — with inspection simulation audit workflows, data integrity self-assessment tools, 483 response management, and corrective action tracking to demonstrate ongoing quality system improvement to FDA inspectors.
Quality by Design (QbD) documentation management for formulation development — covering design of experiments (DoE), critical quality attribute (CQA) identification, critical process parameter (CPP) definition, and design space documentation supporting regulatory submissions aligned with ICH Q8.
Quality documentation management for parallel regulatory submissions across FDA, EMA, PMDA, Health Canada, TGA, and other global health authorities — with jurisdiction-specific document versioning, submission readiness tracking, and health authority query response management.
EU GMP Annex 1 (2022 revision) and FDA aseptic processing guidance-aligned quality management for sterile drug products — covering environmental monitoring, media fill management, aseptic process validation, contamination control strategy (CCS) documentation, and clean room qualification management. CQ.AI™ environmental monitoring trend analysis detects potential contamination events before they compromise sterile products.
EU GMP Annex 1 (2022)-required Contamination Control Strategy documentation — with systematic risk assessment of contamination sources, linkage to environmental monitoring data, cleaning validation evidence, and personnel qualification records in one connected quality system.
EM programme management for clean rooms and aseptic processing areas — monitoring schedule management, data capture integration from particle counters and microbial monitoring, alert and action limit trending, excursion investigation, and trending reports for regulators.
Cleaning validation protocol management, residue limit calculations (HBEL/PDE-based), cleaning validation reports, and worst-case product assessments — with revalidation triggers linked to formulation or equipment changes and visual inspection qualification tracking.
Aseptic gowning qualification management — qualification protocol tracking, periodic re-qualification scheduling, glove integrity monitoring, and personnel contamination rate analytics with automatic requalification triggers when contamination events exceed defined thresholds.
Media fill programme management — scheduling, batch record generation, results capture, and investigation workflow for media fill failures. Aseptic process simulation protocols with CCS linkage and revalidation tracking for changes impacting aseptic process integrity.
Quality management purpose-built for CMOs and CDMOs serving multiple pharmaceutical clients — with client-segregated quality records, multi-client SOP management, client-specific quality agreements, and configurable access controls ensuring each client's data remains isolated while sharing the same GMP quality system infrastructure.
Quality/technical agreement lifecycle management — creation, negotiation, approval, periodic review, and version control for agreements with pharmaceutical sponsors. Automatic alerts when agreements are due for review and linkage to client-specific quality requirements in manufacturing workflows.
Structured technology transfer project management — from sponsor to CMO, from development to commercial manufacturing, or between manufacturing sites. Transfer documentation, comparative batch data, validation equivalence, and regulatory notification workflows for all jurisdictions where the product is approved.
Manage client and regulatory GMP audit programmes across your CMO operations — scheduling, evidence preparation, audit execution, observation response, and CAPA tracking. Client audit history linked to quality agreement compliance and contract renewal cycles.
Real-time quality metrics dashboards segmented by client, product, and manufacturing campaign — with configurable client quality reports, batch yield analytics, deviation rate trending, and CAPA cycle time KPIs that demonstrate your CMO's quality performance to sponsoring pharmaceutical companies.
GMP inspection readiness management for CMOs facing simultaneous FDA, EMA, MHRA, and TGA inspection programmes — with inspection preparation workflows, data integrity self-assessment, prior inspection observation tracking, and regulatory response document management.
GCP and GLP-aligned quality management for pharmaceutical R&D and clinical operations — covering clinical trial quality management, investigational medicinal product (IMP) quality, protocol deviation management, and GLP laboratory quality. CQ bridges the quality gap between R&D and commercial manufacturing, ensuring quality intelligence built during development carries forward into the GMP environment.
GCP-aligned quality management for clinical trial oversight — protocol deviation management, site audit workflows, investigator qualification tracking, and clinical quality management plan (CQMP) implementation. Connected to the commercial QMS for seamless quality handover at the development-to-manufacturing transition.
Good Laboratory Practice quality management for non-clinical safety studies — study plan management, GLP audit workflows, raw data integrity controls, and facility inspection management. Integrated with the QMS CAPA system for GLP laboratory corrective actions that feed into the product development risk assessment.
Investigational Medicinal Product quality management — QP certification workflows, clinical batch record management, IMP labelling control, clinical site distribution tracking, and temperature excursion management for IMP supply chains supporting early-phase and pivotal clinical trials.
ICH Q8-aligned pharmaceutical development documentation — experimental design records, CQA/CPP characterisation data, design space definition, and risk assessment documentation supporting regulatory submissions. Linked to process validation and commercial manufacturing records for lifecycle management.
Structured transition management from clinical to commercial GMP manufacturing — knowledge transfer documentation, process comparability data, regulatory package alignment, and quality system readiness assessment for the first commercial batch. Ensures knowledge built in development is not lost at the commercial handover.
Pre-configured for the full spectrum of pharmaceutical regulatory requirements — so your quality team configures once and maintains continuous compliance across all global regulatory obligations simultaneously.
cGMP regulations for finished pharmaceuticals. CQ workflows map directly to all subparts — covering production and process controls, laboratory controls, records and reports, returned and salvaged drug products, and complaint handling.
EU GMP requirements across Chapters 1–9 and critical Annexes — with dedicated workflows for Annex 1 (sterile manufacturing, 2022 revision) and Annex 11 (computerised systems), including Contamination Control Strategy requirements.
International Council for Harmonisation pharmaceutical quality guidelines — adopted into FDA and EMA regulations and forming the global framework for pharmaceutical quality systems, risk management, and lifecycle management.
Computer system validation framework and electronic records/signatures compliance — with GAMP 5 risk-based approach, IQ/OQ/PQ documentation packages, and ongoing Part 11 compliance maintenance throughout the system lifecycle.
Pharmaceutical Inspection Cooperation Scheme (PIC/S), WHO GMP, and Health Canada Division 2 compliance — enabling manufacturers operating in multiple markets to manage all global GMP obligations within one quality system aligned with international inspection expectations.
Occupational health and safety and environmental management integrated with the GMP quality system — ISO 45001 incident management, OSHA/HSE compliance, COSHH potent compound management, and ISO 14001 environmental performance tracking for pharmaceutical manufacturing sites.
Good Clinical Practice and Good Laboratory Practice quality management — clinical trial oversight, site audit management, protocol deviation tracking, and investigational medicinal product quality for pharmaceutical companies running integrated R&D and commercial quality systems.
Biologics, vaccines, and advanced therapy medicinal product (ATMP) regulatory compliance — FDA 21 CFR Part 600-series, EU ATMP Regulation (1394/2007), WHO biologicals guidance, and EMA CHMP biological product guidelines.
From early development through commercialisation and post-approval lifecycle management — every quality, compliance, and safety workflow is connected.
The FDA issued over 190 warning letters in FY2024. The manufacturers who avoided them share one characteristic — quality systems that make compliance visible in real time, not retrospectively. CQ gives you the live quality intelligence to lead a GMP-compliant organisation proactively, not reactively.
Pharmaceutical QA managers spend a disproportionate amount of their working week on administrative tasks — chasing deviation approvals, manually compiling batch record review packages, tracking CAPA status across spreadsheets. CQ automates every one of these workflows so your expertise is directed at solving quality problems, not managing quality paperwork.
Post-approval change management, annual product reviews, and regulatory inspection preparation require immediate access to quality system records. CQ gives regulatory affairs professionals instant access to the deviation histories, validation records, CAPA evidence, and change control documentation that regulatory agencies expect — without waiting for QA to compile packages manually.
The QP's batch release decision is only as reliable as the quality system evidence behind it. CQ gives Qualified Persons immediate access to every piece of evidence required for batch certification — deviation status, OOS investigation outcomes, CAPA effectiveness, supplier certificate status, and validation currency — in one GxP-validated, auditable system.
Pharmaceutical procurement decisions carry GMP implications that procurement managers in other industries never face. Every raw material and API supplier must be GMP-qualified, monitored, and managed as an extension of your quality system. PartnerQuest gives procurement leadership the tools to manage GMP supplier quality with the rigour FDA and EU GMP require — without slowing sourcing timelines.
A warning letter costs more than just the remediation expense. It triggers consent decrees, import alerts, product withdrawals, and reputational damage that takes years to recover from. ComplianceQuest is the infrastructure investment that prevents that outcome — delivering the quality system maturity that regulators expect from enterprise pharmaceutical manufacturers operating at global scale.
Veeva dominates clinical. MasterControl owns document management. TrackWise serves enterprise legacy. ComplianceQuest is the only platform that unifies GxP QMS, EHS, supplier quality, and AI intelligence — natively on Salesforce — for mid-to-large pharmaceutical manufacturers ready for the next generation of quality management.
CQ.AI™ is trained on millions of quality records from regulated pharmaceutical environments — detecting deviation patterns, predicting OOS events, identifying potential data integrity risks, automating APR/PQR data compilation, and conducting pre-inspection gap analyses. This is purpose-built pharmaceutical AI, not a generic language model with a compliance wrapper applied.
Built natively on Salesforce, CQ integrates with SAP, Oracle, LIMS (LabWare, STARLIMS), MES, and ERP without custom middleware. LIMS results push deviations directly into the QMS. Batch genealogy from ERP enriches change control workflows. One sign-on, one data model, one audit trail — across quality, commercial, and regulatory operations. Veeva Vault has a closed ecosystem. TrackWise requires complex middleware. CQ connects everything.
Unlike platforms that require your team to build GxP compliance through extensive configuration and custom validation work, CQ is GxP-compliant from the ground up. IQ/OQ/PQ documentation packages, GAMP 5 risk-based validation, 21 CFR Part 11 and EU Annex 11 controls — included, not configured. Your computer system validation programme starts weeks ahead of where it would with any alternative.
Veeva covers clinical. MasterControl covers quality documents. TrackWise covers enterprise QMS. None of them unifies GxP quality management with occupational safety (ISO 45001), potent compound management, environmental compliance (ISO 14001), and GMP supplier quality in one validated platform. CQ does — giving pharmaceutical manufacturers one system for every regulatory obligation, not four separate tools.
Every link below is a dedicated resource page covering a specific solution, pharma sector, or regulatory standard — built to answer your exact compliance question.
Subpart-by-subpart GMP self-assessment checklist for pharmaceutical manufacturers — used to identify gaps before FDA inspections. Free download.
Practical implementation guide for the revised Annex 1 requirements — covering CCS, environmental monitoring, aseptic process simulation, and media fill expectations.
GMP-aligned deviation investigation templates covering root cause analysis, impact assessment, CAPA plan, and effectiveness check — aligned with FDA and EU GMP expectations.
On-demand webinar on pharmaceutical data integrity requirements — covering audit trail controls, 21 CFR Part 11, EU Annex 11, and CQ.AI™ data integrity monitoring capabilities.
ComplianceQuest offers a comprehensive GxP-validated platform covering the full breadth of pharmaceutical quality and compliance management: Quality Management including deviation management, OOS/OOT investigation, CAPA management, pharmaceutical change control, SOP document management, audit management, complaint management, and GMP training management; Validation and CSV support including computer system validation documentation (IQ/OQ/PQ packages), process validation management, cleaning validation, equipment qualification, and continued process verification (CPV); Supplier Quality through PartnerQuest for GMP supplier qualification, audit management, SCAR management, and supplier performance monitoring; Environmental Health and Safety including potent compound occupational exposure management, ISO 45001 safety management, and ISO 14001 environmental compliance; and CQ.AI™ pharmaceutical intelligence for predictive deviation analytics, data integrity monitoring, inspection readiness gap analysis, and APR/PQR automation.
All modules run on a single Salesforce-native platform with GxP controls by design — 21 CFR Part 11 e-signatures and audit trails on every record, EU Annex 11 computerised system controls, and GAMP 5 risk-based validation support throughout.
ComplianceQuest is built with 21 CFR Part 11 and EU GMP Annex 11 compliance by design — not as an add-on configuration. Every record in the system requires time-stamped, non-repudiable electronic signatures for approvals. Complete, immutable audit trails are automatically generated for every record creation, modification, and deletion. Role-based access controls ensure only authorised users can access, create, or modify records. Unique user identifiers are enforced across all system interactions.
For computer system validation (CSV), ComplianceQuest provides IQ/OQ/PQ validation documentation packages, test scripts, and GAMP 5 risk-based validation documentation — dramatically reducing the time and cost of validating CQ for GxP use. The platform is hosted on Salesforce's SOC 2 Type II certified infrastructure, with system change management controlled through Salesforce's validated release management process. This means your ongoing Part 11 compliance is maintained by Salesforce's infrastructure team — reducing the CSV maintenance burden for your internal validation team.
ComplianceQuest provides structured pharmaceutical deviation management aligned with 21 CFR Part 211 and EU GMP Chapter 6 requirements. Deviations are classified (planned/unplanned, minor/major/critical), assigned to investigators, routed through configurable investigation phases with defined timelines and escalation rules, linked to impact assessments covering batch disposition, regulatory reporting obligations, and validation currency, and automatically trigger CAPA initiation when root cause investigation is complete.
For Out-of-Specification (OOS) investigations, CQ supports the FDA-guidance-aligned two-phase investigation structure — Phase I laboratory investigation (potential assignable laboratory cause) and Phase II full investigation (broader process and material cause investigation). Results are linked directly to batch records and stability data. Out-of-Trend (OOT) monitoring is connected to stability management for automatic trending alerts. CQ.AI™ cross-references historical deviations and OOS events across batches, equipment, materials, and operators to surface pattern-based root causes that manual investigation may miss.
ComplianceQuest supports the full spectrum of pharmaceutical regulatory requirements within a single platform: 21 CFR Part 210 and 211 (FDA cGMP for finished pharmaceuticals); 21 CFR Part 11 (electronic records and signatures); 21 CFR Part 600-series (FDA biologics regulations); EU GMP Annex 1 (sterile manufacturing — 2022 revision including Contamination Control Strategy); EU GMP Annex 11 (computerised systems); EU GMP Annex 15 (qualification and validation); ICH Q8 (pharmaceutical development / QbD), Q9 (quality risk management), Q10 (pharmaceutical quality system), Q11 (drug substance development and manufacture), Q12 (product and process lifecycle management); GAMP 5 (computer system validation); PIC/S GMP guidelines; WHO GMP; Health Canada Division 2; and GCP/GLP quality management for R&D and clinical operations.
For safety and environmental obligations: ISO 45001 (occupational health and safety), ISO 14001 (environmental management), COSHH/OSHA HazCom for potent compound and chemical management, and OEL/OEB-based occupational exposure management for API and pharmaceutical manufacturing environments.
ComplianceQuest is specifically configured for the unique quality management challenges of Contract Manufacturing Organisations and Contract Development and Manufacturing Organisations — who must simultaneously manage GMP obligations for multiple pharmaceutical sponsor clients within a single quality system infrastructure.
CQ provides client-segregated quality records with configurable access controls ensuring each client's batch records, deviation histories, and quality event data are isolated from other clients while sharing the same GMP system infrastructure. Quality and technical agreement lifecycle management with version control and automatic periodic review triggers ensures sponsor agreements are current. Multi-client quality metrics dashboards allow CMO quality leadership to monitor performance across all client programmes simultaneously. Technology transfer project management with structured documentation and regulatory equivalence assessment supports both sponsor-to-CMO and development-to-commercial manufacturing transfers. Client audit management — including sponsor GMP audit scheduling, evidence preparation, and observation response tracking — is fully integrated with the quality system.
CQ.AI™ is trained on millions of quality records from regulated pharmaceutical environments — giving it domain-specific intelligence unavailable in any general-purpose AI tool applied to quality management. For pharmaceutical teams specifically, CQ.AI™ delivers predictive deviation analytics that identify emerging process quality risks before the next investigation is opened; automatic OOS and OOT pattern detection across batches, equipment, and raw material lots; data integrity monitoring across audit trail records to detect anomalies that could indicate Part 11 compliance risks before they become FDA observations; pre-inspection gap analysis comparing your quality system records against common FDA 483 and EMA deficiency patterns to prioritise remediation before the inspection; intelligent APR/PQR data aggregation compiling all required annual product review data automatically from your quality system records; and intelligent SOP and document analysis that identifies gaps, inconsistencies, and outdated references across your document library without manual review.
Get a 30-minute demo tailored to your pharma sector, regulatory scope, and current quality system challenges. No commitment required.
Please confirm your details
By submitting this form you agree that we can store and process your personal data as per our Privacy Statement. We will never sell your personal information to any third party.
Enter Captcha